

Item 8.01. Other Events.

On December 6, 2016, TG Therapeutics, Inc. issued press releases announcing presented data from three combination studies involving the Company's lead compounds, TGR-1202 and TG-1101 (ublituximab) in combination with other compounds, at the 58th American Society of Hematology (ASH) Annual Meeting, being held in San Diego, CA. A copy of the press release is being filed as Exhibit 99.1 and incorporated in this Item by reference. In addition, on December 6, 2016 the Company also issued a press releasing announcing that the target enrollment for the GENUINE Phase 3 study has been met and enrollment will be closed shortly. A copy of the press release is being filed as Exhibit 99.2 and incorporated in this Item by reference.

Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

99.1 Press Release, dated December 6, 2016.

99.2 Press Release, dated December 6, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TG Therapeutics, Inc.
(Registrant)

Date: December 6, 2016

By: /s/ Sean A. Power
Sean A. Power
Chief Financial Officer

INDEX TO EXHIBITS

Exhibit

Number Description

99.1. Press Release, dated December 6, 2016.

99.2 Press Release, dated December 6, 2016.